SODIUM PENTOBARBITAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Pentobarbital, and when can generic versions of Sodium Pentobarbital launch?
Sodium Pentobarbital is a drug marketed by Anabolic, Elkins Sinn, Everylife, Halsey, Ivax Sub Teva Pharms, Parke Davis, Perrigo, Purepac Pharm, Valeant Pharm Intl, Watson Labs, Wyeth Ayerst, and Nexgen Pharma Inc. and is included in thirteen NDAs.
The generic ingredient in SODIUM PENTOBARBITAL is pentobarbital sodium. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentobarbital sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Pentobarbital
A generic version of SODIUM PENTOBARBITAL was approved as pentobarbital sodium by SAGENT PHARMS INC on May 23rd, 2016.
Summary for SODIUM PENTOBARBITAL
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 29 |
Patent Applications: | 3,709 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SODIUM PENTOBARBITAL at DailyMed |